+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of prucalopride in adults and children with chronic constipation



Efficacy and safety of prucalopride in adults and children with chronic constipation



Expert Opinion on PharmacoTherapy 16(3): 407-416



Chronic constipation (CC) is a debilitating condition with high prevalence rates both in children and adults. Despite the broad range of medical and pharmaceutical treatments, the bowel function does not restore in a fair amount of patients. Prucalopride is a first-in-class selective, high affinity serotonin 5-hydroxytryptamine type 4 (5-HT4) receptor agonist promoting gastro-intestinal prokinetic activity and has been evaluated for the treatment of CC. A PubMed search (1965 - 2014) using the following terms alone or in combination: prucalopride, 5-HT4, R093877, safety, toxicity, pharmacokinetics, pharmacodynamics, transit, cardiac, human ether-a-go-go related gene (hERG), arrhythmia, potassium current, elderly, children. Prucalopride, a highly selective 5-HT4 receptor agonist, stimulates gastrointestinal motility and has been proven to be effective in the treatment of CC in adults by increasing stool frequency, reducing constipation-related symptoms and improving quality of life (QoL). The safety and tolerability have been proven to be excellent. More research would be preferable on the effect of prucalopride on men, children and in other gastrointestinal motility disorders.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057738223

Download citation: RISBibTeXText

PMID: 25539475

DOI: 10.1517/14656566.2015.996547


Related references

The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology 116(4 Part 2): A1043, 1999

Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opinion on Drug Metabolism and Toxicology 8(10): 1327-1335, 2012

Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterology Journal 1(1): 48-59, 2013

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. Digestive Diseases and Sciences 61(8): 2357-2372, 2016

Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Digestive Diseases and Sciences 55(10): 2912-2921, 2010

Sa1390 Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized Controlled Clinical Trials. Gastroenterology 148(4): S-311, 2015

PWE-252 Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomised, double-blind, placebo-controlled trial. Gut 64(Suppl 1): A323.2-A324, 2015

Efficacy and Safety of Prucalopride in Children With Functional Constipation: Results of a Multicenter, Placebo-Controlled, Phase 3 Trial. Gastroenterology 146(5): S-172, 2014

929g Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomized, double-blind, placebo-controlled trial. Gastroenterology 146(5): S-160, 2014

A double-blind, placebo-controlled evaluation of safety and efficacy of 12-week, twice-daily treatment with prucalopride in patients with chronic constipation. Gastroenterology 116(4 Part 2): A1055, 1999

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Alimentary Pharmacology and Therapeutics 29(3): 315-328, 2009

Use of prucalopride in adults with chronic idiopathic constipation. Expert Review of Clinical Pharmacology 12(7): 579-589, 2019

Tu1394 The Efficacy and Safety of Oral Prucalopride in Female Patients With Chronic Constipation Who Had Failed Laxative Therapy (Ema-Authorised Population) is Similar to That of the Complete Itt Population in the Initial Pivotal Trials: Pooled Data Analysis. Gastroenterology 142(5): S-820-S-821, 2012

Evaluation of the efficacy of prucalopride (resolor) in the treatment of patients with chronic constipation. Terapevticheskii Arkhiv 85(12): 60-64, 2013

S1300 Long-Term Efficacy of Oral Prucalopride in Patients With Chronic Constipation. Gastroenterology 138(5): S-223-S-224, 2010